79
51
Growth Score
-10 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
372271
An Emerging Biotechnology Company
Acquired by 
Abcam
Weimin Zhu: Co - Founder & SVP, Antibody TechnologyPast Role: University of California, San Francisco, Senior Associate Specialist
Guo Liang Yu: Co-Founder, President & CEOPast Role: Crown Bioscience, Executive Chairman
About the Company
Epitomics, an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in
vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People’s Republic of China.
